Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its ...
Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.
In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.
Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results